- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Epilepsy
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1344KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 178KB)
Lacosamide – March 2021
Lacosamide: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg, Tablet 200 mg, Oral solution 10 mg per mL, 200 mL; Vimpat®
Last updated
2 July 2021